Table 3.
Median time to onset (95% CI) of common treatment-emergent adverse events
| Sonidegib 200 mg n = 79 |
Vismodegib 150 mg n = 119 |
HR (95% CI) P value |
|||
|---|---|---|---|---|---|
| Median time to onset (95% CI), months | Number of events | Median time to onset (95% CI), months | Number of events | ||
| Muscle spasm | 2.1 (1.9–3.2) | 43 | 1.2 (0.9–1.5) | 84 |
0.57 (0.40–0.83) 0.0029 |
| Dysgeusia | 3.7 (2.8–4.9) | 35 | 1.4 (1.0–1.7) | 84 |
0.38 (0.26–0.56) < 0.0001 |
| Alopecia | 5.5 (4.7–6.4) | 39 | 2.9 (2.5–3.5) | 69 |
0.53 (0.36–0.78) 0.0014 |
| Diarrhea | 6.5 (1.3–10.3) | 25 | 1.3 (0.7–3.9) | 30 |
0.20 (0.12–0.34) < 0.0001 |
| Nausea | 3.2 (1.5–4.6) | 31 | 1.0 (0.4–4.3) | 23 |
0.31 (0.18–0.54) < 0.0001 |
| Fatigue | 1.1 (0.5–3.7) | 26 | 1.4 (0.5–4.0) | 23 |
1.27 (0.73–2.23) 0.4068 |
| Weight decrease | 6.5 (4.7–8.3) | 24 | 5.8 (3.8–9.8) | 19 |
0.89 (0.49–1.63) 0.7237 |
CI confidence interval, HR hazard ratio